Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP cut its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 15.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,234,455 shares of the company's stock after selling 751,521 shares during the quarter. Wellington Management Group LLP owned 4.96% of Syndax Pharmaceuticals worth $55,979,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. DnB Asset Management AS grew its holdings in shares of Syndax Pharmaceuticals by 32.1% in the fourth quarter. DnB Asset Management AS now owns 22,943 shares of the company's stock valued at $303,000 after purchasing an additional 5,581 shares in the last quarter. Simplify Asset Management Inc. grew its holdings in shares of Syndax Pharmaceuticals by 20.8% in the fourth quarter. Simplify Asset Management Inc. now owns 147,641 shares of the company's stock valued at $1,952,000 after purchasing an additional 25,456 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Syndax Pharmaceuticals during the fourth quarter worth $219,000. Teacher Retirement System of Texas boosted its stake in Syndax Pharmaceuticals by 18.7% during the fourth quarter. Teacher Retirement System of Texas now owns 22,769 shares of the company's stock worth $301,000 after buying an additional 3,585 shares during the period. Finally, AlphaQuest LLC boosted its stake in Syndax Pharmaceuticals by 32.3% during the fourth quarter. AlphaQuest LLC now owns 23,623 shares of the company's stock worth $312,000 after buying an additional 5,765 shares during the period.

Remove Ads

Syndax Pharmaceuticals Stock Down 12.8 %

Shares of SNDX stock traded down $1.48 during trading hours on Thursday, hitting $10.05. 1,197,160 shares of the company's stock were exchanged, compared to its average volume of 1,550,029. The firm has a market cap of $864.31 million, a P/E ratio of -2.77 and a beta of 1.28. The firm has a 50 day moving average of $13.81 and a two-hundred day moving average of $15.43. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $9.66 and a fifty-two week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to analyst estimates of $86.32 million. On average, equities analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Scotiabank dropped their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a research note on Wednesday, January 8th. HC Wainwright reiterated a "buy" rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. JPMorgan Chase & Co. lifted their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, March 20th. Citigroup decreased their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Finally, StockNews.com upgraded Syndax Pharmaceuticals to a "sell" rating in a research note on Thursday. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $36.20.

Insider Activity at Syndax Pharmaceuticals

In other news, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the transaction, the chief executive officer now directly owns 300,121 shares in the company, valued at approximately $4,651,875.50. This represents a 4.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Neil Gallagher sold 4,618 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the transaction, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. The trade was a 5.15 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,683 shares of company stock valued at $336,087. 4.10% of the stock is owned by insiders.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).